Renovacor, Inc.

Chardan Healthcare Acquisitions 2 Corp. (Nasdaq: CHAQ), a blank-check company sponsored by Chardan Capital Markets, completed its IPO in 2020 targeting the healthcare and life sciences sector. On March 23, 2021, the company filed an 8-K disclosing a proposed business combination with Renovacor, Inc., a clinical-stage gene therapy company focused on genetic heart failure treatments, including AAV-based therapies targeting the BAG3 pathway. The announcement marked a notable entry into the cardiovascular gene therapy space for the Chardan-backed SPAC. For the full filing history, deal terms, sponsor background, and status updates on CHAQ and thousands of other SPACs, sign up for complete data access at SpacDesk.